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OBJECTIVES The aim of this study was to examine the effects of essential hypertension on cardiac
autonomic function in type 2 diabetic patients.
BACKGROUND Hypertension is common in type 2 diabetic patients and is associated with a high mortality.
However, the combined effects of type 2 diabetes and essential hypertension on cardiac
autonomic function have not been fully elucidated.
METHODS Thirty-three patients with type 2 diabetes were assigned to a hypertensive diabetic group
(n 5 15; age: 56 6 8 years, mean 6 SD) or an age-matched normotensive diabetic group
(n 5 18, 56 6 6 years). Cardiac autonomic function was assessed by baroreflex sensitivity
(BRS), heart rate variability (HRV), plasma norepinephrine concentration and cardiac
123I-metaiodobenzylguanidine (MIBG) scintigraphic findings.
RESULTS Baroreflex sensitivity was lower in the hypertensive diabetic group than it was in the
normotensive diabetic group (p , 0.05). The early and delayed myocardial uptake of
123I-MIBG was lower (p , 0.01 and p , 0.05, respectively), and the percent washout rate
of 123I-MIBG was higher (p , 0.05) in the hypertensive diabetic group. However, the high
frequency (HF) power and the ratio of low frequency (LF) power to HF power (LF/HF) of
HRV and plasma norepinephrine concentration were not significantly different. The
homeostasis model assessment index was higher in the hypertensive diabetic group than it was
in the normotensive diabetic group (p , 0.01).
CONCLUSIONS Our results indicate that essential hypertension acts synergistically with type 2 diabetes to
depress cardiac reflex vagal and sympathetic function, and the results also suggest that insulin
resistance may play a pathogenic role in these processes. (J Am Coll Cardiol 2001;38:232–7)
© 2001 by the American College of Cardiology
Diabetes mellitus and hypertension frequently occur con-
currently and probably have synergistic detrimental effects
on the cardiovascular system (1–3). The mortality in dia-
betic patients with hypertension is several fold higher than
it is in normotensive diabetic patients (4). Progression of
atherosclerosis to occlusive coronary artery disease can
explain the high mortality in hypertensive diabetic patients.
However, sudden and unexpected deaths, probably caused
by ventricular tachyarrhythmias, have often been attributed
to diabetic cardiac neuropathy (5–7). Previous studies have
demonstrated that both diabetes and hypertension impair
cardiac autonomic function (8–12), suggesting that the
association of these two diseases promotes cardiac auto-
nomic dysfunction. However, the combined effects of dia-
betes and hypertension on cardiac autonomic control have
not been fully elucidated.
Technical advances, including the measurement of
baroreflex sensitivity (BRS), heart rate variability (HRV)
and cardiac 123I-metaiodobenzylguanidine (MIBG) scintig-
raphy, have allowed the precise assessment of cardiac
autonomic function (8,13). In this study, we determined
BRS, HRV and cardiac 123I-MIBG scintigraphic findings
in diabetic patients in order to determine the impact of
essential hypertension on cardiac vagal and sympathetic
function in type 2 diabetic patients.
METHODS
Patients. Thirty-three Japanese patients with type 2 dia-
betes mellitus (age: 56 6 7 years, mean 6 SD; 15 women
and 18 men) who were admitted to our department were
enrolled in this study. The clinical characteristics of these
patients are summarized in Table 1. None of the patients
had organic heart disease as determined by physical exam-
ination, chest X-ray, 12-lead electrocardiogram (ECG),
echocardiography, treadmill exercise ECG testing and
201thallium cardiac scintigraphy. Essential hypertension was
defined as diastolic blood pressure (BP) $90 mm Hg,
systolic BP $140 mm Hg or self-reported use of antihy-
pertensive medication (12). Fifteen of the 33 patients met
these criteria and were assigned to the hypertensive diabetic
group, while the remaining 18 patients were assigned to the
normotensive diabetic group. In the hypertensive diabetic
group, eight patients were treated with calcium channel
antagonists, four patients with angiotensin-converting en-
zyme inhibitors and one patient with both. These medica-
tions were discontinued at least two days before cardiac
autonomic function testing. No patients were treated with
diuretics, beta-adrenergic blocking agents or alpha blockers.
Patients who were treated with insulin or had albuminuria
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($500 mg/day) or abnormal plasma creatine concentrations
($1.2 mg/dl) were excluded from the study.
The study was approved by the ethics review board of our
institution, and written informed consent was obtained
from all patients.
Echocardiography. M-mode two-dimensional echocardi-
ography and cardiac Doppler recordings were obtained by
means of a phase-array echo-Doppler system. Echocardio-
grams were obtained in a standard manner using standard
parasternal, short-axis and apical views. Left ventricular
(LV) mass was calculated according to a previous study (14):
LV mass 5
1.04 ~@LVIDd 1 IVSTd 1 PWTd#3 2 LVIDd3! 2 14 g,
where LVIDd 5 LV internal dimension at end-diastole;
IVSTd 5 intraventricular septal thickness at end-diastole
and PWTd 5 posterior wall thickness at end-diastole. Left
ventricular mass was divided by body surface area to
calculate the LV mass index. Pulsed Doppler recordings
were made from the standard apical four-chamber view.
Mitral inflow velocity was recorded with the sample volume
at the mitral annulus level; the average of $3 cardiac cycles
was taken. The following measurements were made: peak
velocity of early ventricular filling (E), peak velocity of late
ventricular filling (A), their ratio (E/A) and deceleration
time.
Measurement of BRS and plasma norepinephrine (NE)
concentration. All subjects were studied while in supine
position in a quiet room with dimmed lights between 9 and
11 AM (15). A catheter was inserted in the right cubital vein,
and arterial BP was recorded noninvasively using tonometry
(Jentow-7700, Nihon Colin, Komaki, Japan). The tono-
metric sensor was attached over the left radial artery. The
accuracy of continuous BP monitoring using this system has
been demonstrated previously (16). Arterial BP and the
standard 12-lead ECG were monitored simultaneously, and
data were stored in a PCM data recorder (RD-200T;
TEAC, Tokyo, Japan). Three-lead precordial Holter ECG
recordings (model-459, Del Mar Avionics, Irvine, Califor-
nia) were also obtained throughout the procedure for
analysis of HRV.
After a waiting period of 30 min to allow cardiovascular
baroreflex mechanisms to stabilize, patients were asked to
breathe at a rate of 15 breaths/min using a metronome to
maximize regularity between respiration and cardiovascular
function. A blood sample was obtained from the venous
catheter for measurement of plasma NE concentration.
Abbreviations and Acronyms
BRS 5 baroreflex sensitivity
ECG 5 electrocardiogram
H/M 5 heart-to-mediastinum
HF 5 high frequency component (0.15 to 0.45 Hz)
HOMA 5 homeostasis model assessment
HRV 5 heart rate variability
LF 5 low frequency component (0.04 to 0.15 Hz)
LV 5 left ventricular
MIBG 5 metaiodobenzylguanidine
NE 5 norepinephrine
WR 5 washout rate
Table 1. Clinical Characteristics of Studied Patients
HD Group
(n 5 15)
ND Group
(n 5 18) p Value
Age (yr) 56 6 8 56 6 6 NS
Gender (women/men) 7/8 8/10 NS
Duration of diabetes (yr) 10.9 6 7.1 9.6 6 8.1 NS
Drug use (%)
SU 47 22 NS
Alpha glucosidase inhibitors 40 39 NS
Troglitazone 6 5 NS
Calcium channel antagonists 60 0 , 0.0005
ACE inhibitors 33 0 , 0.05
BMI (kg/m2) 27.6 6 3.9 24.1 6 3.6 , 0.05
HR (beats/min) 67 6 9 67 6 8 NS
SBP (mm Hg) 145 6 15 113 6 30 , 0.001
DBP (mm Hg) 83 6 10 73 6 12 , 0.05
FPG (mmol/l) 8.9 6 3.2 8.0 6 2.4 NS
HbA1c (%) 8.1 6 1.6 8.8 6 2.1 NS
F-IRI (pmol/l) 7.9 6 3.6 5.3 6 2.1 , 0.05
HOMA index 3.1 6 1.7 1.8 6 0.7 , 0.01
T-Chol (mg/dl) 209 6 34 191 6 40 NS
TGL (mg/dl) 137 6 72 103 6 43 NS
HDL-c (mg/dl) 45 6 9 45 6 9 NS
UA (mg/dl) 5.9 6 1.1 4.5 6 1.1 , 0.001
Data are mean 6 SD.
ACE 5 angiotensin-converting enzyme; BMI 5 body mass index; DBP 5 diastolic blood pressure; FPG 5 fasting plasma
glucose; F-IRI 5 fasting immunoreactive insulin; HbA1c 5 hemoglobin A1c; HD 5 hypertensive diabetic; HDL-c 5
high-density lipoprotein cholesterol; HOMA 5 homeostasis model assessment; HR 5 heart rate; ND 5 normotensive diabetic;
SBP 5 systolic blood pressure; SU 5 sulfonylurea; TGL 5 triglyceride; T-Chol 5 total cholesterol; UA 5 uric acid.
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Baroreflex sensitivity was assessed by the phenylephrine
method, as previously described (15). Phenylephrine (2 to
3 mg/kg) was injected over 15 s to obtain a 15 to 40 mm Hg
systolic BP increase. Baroreflex sensitivity was calculated as
the slope of the linear regression line relating systolic BP
changes to RR interval changes. Regression lines with more
than 20 data points and a correlation coefficient (r) .0.8
were accepted for analysis. The mean of the two slope values
was taken as the BRS value.
HRV. Heart rate variability was analyzed using a 300-s
interval of Holter ECG recording immediately before phen-
ylephrine injection. The power spectrum of the RR interval
was computed by a fast Fourier transform and expressed as
the area under the power spectrum (17). We calculated the
power of two spectral bands, the low-frequency component
at 0.04 to 0.15 Hz (LF) and the high-frequency component
at 0.15 to 0.40 Hz (HF). Measured values of HRV were
transformed using a natural logarithm because their distri-
butions were skewed. The ratio of LF to HF (LF/HF) was
also computed.
Cardiac 123I-MIBG scintigraphy. Planar and single pho-
ton emission computed tomography studies were per-
formed both 15 min (early) and 4 h (delayed) after the
injection of 111 MBq of 123I-MIBG using a rotating
gamma camera (ZLC 7500; Siemens, Munich, Germany).
Data were analyzed with computer-based analysis software
(SCINTIPAC; Shimadzu, Kyoto, Japan). The anterior
planar images of the early and delayed 123I-MIBG studies
were analyzed visually. For semiquantitative analysis, re-
gions of interest were drawn over the whole heart and a
10-mm 3 10-mm area over the upper mediastinum on the
early and delayed planar images to calculate the mean
heart-to-mediastinum (H/M) ratio. After correcting for the
physical decay of 123I, the percent washout rate (WR) of the
tracer from the myocardium was determined for the 4-h
period.
Insulin resistance. Insulin resistance was evaluated by the
homeostasis model assessment (HOMA) index 5 (fasting
plasma insulin [pmol/l] 3 fasting plasma glucose [mmol/l])/
22.5 (18).
Statistical analysis. Data are presented as mean 6 SD.
Differences between the two groups were analyzed by
unpaired Student t test, chi-square test or Fisher exact
probability test. A value of p ,0.05 was considered statis-
tically significant.
RESULTS
Clinical characteristics of the patients. As demonstrated
in Table 1, the mean age was similar between the groups.
No significant differences were observed between the two
groups with respect to gender, duration of diabetes or
number of patients treated with sulfonylurea, alpha gluco-
sidase inhibitors and troglitazone. Calcium channel antag-
onists and angiotensin-converting enzyme inhibitors were
used in the hypertensive diabetic groups but not in the
normotensive diabetic group (p , 0.0005 and p , 0.05,
respectively). Body mass index was greater in the hyperten-
sive diabetic group than it was in the normotensive diabetic
group (p , 0.05). There were no significant differences in
the fasting plasma glucose and hemoglobin A1c between
the groups. The hemodynamic data in Table 1 were
obtained immediately before the BRS assessment. Although
the resting heart rate was not significantly different, systolic
and diastolic BP were higher in the hypertensive diabetic
group than in the normotensive diabetic group (p , 0.001
and p , 0.05, respectively). Both the fasting plasma insulin
concentration and HOMA index were higher in the hyper-
tensive diabetic group than in the normotensive diabetic
group (p , 0.05 and p , 0.01, respectively). Plasma total
cholesterol, triglyceride and HDL-cholesterol were not
significantly different between the two groups. However, the
level of uric acid was higher in the hypertensive diabetic
group than it was in the normotensive diabetic group (p ,
0.001).
Echocardiographic findings. Table 2 summarizes the
echocardiographic findings. There were no significant dif-
ferences in the LV dimensions at end-diastole and end-
systole, ejection fraction or posterior wall thickness at
end-diastole between the two groups. In contrast, left atrial
dimension and intraventricular septal thickness at end-
diastole were greater in the hypertensive diabetic group than
in the normotensive diabetic group (p , 0.001 and p ,
0.005, respectively). There was no significant difference in
LV mass index between the groups. With respect to the LV
diastolic function, the peak velocity of A was increased, and
the E/A ratio was decreased more in the hypertensive
diabetic group than it was in the normotensive diabetic
group (p , 0.005 and p , 0.05, respectively). However,
there was no significant difference in the deceleration time
between the groups.
Table 2. Echocardiographic Findings
HD Group
(n 5 15)
ND Group
(n 5 18) p Value
LAD (mm) 37 6 3 33 6 3 , 0.001
LVIDd (mm) 49 6 3 47 6 5 NS
LVIDs (mm) 31 6 3 31 6 4 NS
EF (%) 74 6 4 71 6 5 NS
IVSTd (mm) 10.1 6 1.1 9.1 6 0.8 , 0.005
PWTd (mm) 9.8 6 1.1 9.2 6 1.1 NS
LV mass (g) 208 6 44 171 6 41 , 0.05
LV mass index (g/m2) 68 6 13 64 6 12 NS
E-peak velocity (cm/s) 58 6 11 61 6 15 NS
A-peak velocity (cm/s) 79 6 14 63 6 15 , 0.005
E/A ratio 0.76 6 0.21 1.04 6 0.40 , 0.05
Deceleration time (ms) 271 6 72 254 6 89 NS
Data are mean 6 SD.
EF 5 ejection fraction; IVSTd 5 interventricular septal thickness at end-diastole;
LAD 5 left atrial dimension; LVIDd 5 left ventricular internal dimension at
end-diastole; LVIDs 5 left ventricular internal dimension at end-systole; PWTd 5
posterior wall thickness at end-diastole.
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Cardiac autonomic function tests. Figure 1 summarizes
the findings of the cardiac autonomic function tests. Barore-
flex sensitivity was lower in the hypertensive diabetic group
than it was in the normotensive diabetic group (5.4 ms/mm
Hg 6 4.2 ms/mm Hg vs. 9.5 ms/mm Hg 6 4.7 ms/mm
Hg, p , 0.05, Fig. 1A). The plasma NE concentration in
the hypertensive diabetic group was similar to that in the
normotensive diabetic group (227 pg/ml 6 89 pg/ml vs.
225 pg/ml 6 84 pg/ml, p 5 NS, Fig. 1B). The analysis of
HRV revealed that the HF power and the LF/HF ratio in
the hypertensive diabetic group were not significantly dif-
ferent from those in the normotensive diabetic group
(4.1 ln-ms2 6 1.0 ln-ms2 vs. 4.1 ln-ms2 6 1.0 ln-ms2, p 5
NS, 1.1 ln-ms2 6 1.1 ln-ms2 vs. 1.3 ln-ms2 6 1.1 ln-ms2,
p 5 NS, respectively, Fig. 1C). Cardiac 123I-MIBG scin-
tigraphy revealed that the H/M ratios at early and delayed
phases were lower in the hypertensive diabetic group than
they were in the normotensive diabetic group (1.97 6 0.29
vs. 2.29 6 0.32, p , 0.01 and 1.90 6 0.29 vs. 2.19 6 0.26,
p , 0.05, respectively, Fig. 1D). The percent WR of
123I-MIBG was higher in the hypertensive diabetic group
compared with the normotensive diabetic group (40.7% 6
9.1% vs. 33.2% 6 10.0%, p , 0.05, Fig. 1D).
DISCUSSION
Main findings. To our knowledge, this is the first study
that compares cardiac autonomic function between diabetic
patients with and without essential hypertension by simul-
taneous assessment of BRS, HRV and 123I-MIBG scintig-
raphy. The main findings were that type 2 diabetic patients
with essential hypertension had a lower BRS and showed
lower myocardial uptake and enhanced clearance of 123I-
MIBG compared with those patients without essential
hypertension. These observations suggest that both cardiac
reflex vagal and sympathetic function in type 2 diabetic
patients may be impaired when associated with essential
hypertension.
Assessment of cardiac vagal function. Analysis of HRV
has been used as a measure of cardiac autonomic control.
Vagal activity is certainly the contributor to the HF com-
ponent of HRV. Baroreflex sensitivity with the phenyleph-
rine method also estimates cardiovascular vagal activity.
These two tests have been widely applied to identify patients
at high risk for sudden cardiac death after myocardial
infarction (MI) (19,20). Although both HF power and BRS
are indexes of vagal activity, they reflect different physiolog-
Figure 1. Comparison of measurements of autonomic function tests between hypertensive diabetic (HD) and normotensive diabetic (ND) patients. (A)
Baroreflex sensitivity (BRS). (B) Plasma norepinephrine (NE) concentration. (C) Heart rate variability (HRV). Power of high-frequency component ([HF]
0.15 to 0.40 Hz, a) and the ratio of the low-frequency power ([LF] 0.04 to 0.15 Hz) to HF power ([LF/HF] b). Values of HRV were transformed using
a natural logarithm because their distributions were skewed. (D) Cardiac 123I-metaiodobenzylguanidine (MIBG) scintigraphic findings. Myocardial uptake
of 123I-MIBG at early (a) and delayed (b) phases. Myocardial uptake of 123I-MIBG is expressed as the mean heart-to-mediastinum (H/M) ratio. (c) Percent
washout rate (WR) of 123I-MIBG. Data are mean 6 SD. *p , 0.05; **p , 0.01. ns 5 not significant.
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ical aspects (i.e., HF power is a marker of tonic vagal activity
whereas BRS is a marker of reflex vagal activity) (15,19–21).
For instance, De Ferrari et al. (21) assessed HRV and BRS
in patients with and without episodes of sustained ventric-
ular tachycardia or ventricular fibrillation after MI and
demonstrated that patients with tachyarrhythmias have
significantly lower BRS compared with those without
tachyarrhythmias, while no significant difference was found
in measures of HRV. Furthermore, the ATRAMI (Auto-
nomic Tone and Reflex After MI) investigators demon-
strated that BRS has strong independent prognostic value
after MI (20). These findings suggest that analysis of BRS
rather than HRV may be more helpful in risk stratification
after MI. In this study, BRS was significantly lower in the
hypertensive diabetic group than it was in the normotensive
diabetic group in spite of a similar HF power. This finding
indicates that BRS may also be more useful in detecting
cardiac vagal dysfunction in hypertensive or diabetic pa-
tients.
Although our study showed that HF power is not affected
by the presence of essential hypertension, the Atheroscle-
rosis Risk In Communities (ARIC) study showed that
hypertension clustered with diabetes has an inverse additive
effect on HRV (12). It is difficult to explain the difference
between the two studies. In the ARIC study, most enrolled
patients were American. Therefore, there may be racial
differences between the two studies. The ARIC study also
included patients with a history of coronary heart disease
and those treated with beta-adrenergic blocking agents.
Severe hypertensive patients may also have been included in
the former study, while our study included only patients
with mild essential hypertension. These factors may explain
the differences observed between the two studies.
Assessment of cardiac sympathetic function. In this
study, cardiac sympathetic function was estimated by three
different methods (plasma NE concentration, HRV and
123I-MIBG scintigraphy). Plasma NE concentration was
similar between the groups. The LF/HF ratio did not differ
between the groups. In contrast, the myocardial uptake of
123I-MIBG was reduced, and its clearance was enhanced in
the hypertensive diabetic group. Although no technique is
currently considered to be the “gold standard” for assessing
human sympathetic function with which other techniques
might be compared (22), these findings suggest that 123I-
MIBG scintigraphy may be fairly sensitive in detecting
cardiac sympathetic dysfunction, at least in the population
we studied (23).
Detrimental effects of essential hypertension on diabetic
neuropathy—possible role of insulin resistance. The two
groups examined in our study were age-matched and had a
similar duration of diabetes. The plasma glucose and hemo-
globin A1c were similar between the groups. Furthermore,
the LV mass index showed no significant difference. The
main difference between the two groups was the arterial BP.
Therefore, the depressed cardiac autonomic function in the
hypertensive diabetic group observed in this study can be
explained by the additive adverse effects of hypertension.
Liao et al. (12) reported that hypertension clustered with
diabetes synergistically influenced cardiac autonomic control
when assessed by HRV. Tamura et al. (24) demonstrated
that the percent WR of 123I-MIBG was increased in
hypertensive diabetic patients compared with healthy sub-
jects, whereas the difference was not statistically different
between normotensive diabetic patients and healthy sub-
jects. Our study did not show a significant difference in
HRV between the two groups. However, BRS and 123I-
MIBG scintigraphy detected depressed cardiac autonomic
function in the hypertensive diabetic group.
With respect to the pathogenesis of essential hyperten-
sion clustered with type 2 diabetes, it is noteworthy that the
body mass index and the HOMA index were higher in the
hypertensive diabetic group than in the normotensive dia-
betic group. These findings suggest the involvement of
insulin resistance in influencing cardiac autonomic control.
In fact, experimental studies have revealed that insulin-
resistant rats with hypertension showed both impaired reflex
vagal activity and increased the WR of 123I-MIBG (25,26).
The report by Liao et al. (12) demonstrated that depressed
HRV in hypertensive diabetic patients is associated with an
increased fasting plasma insulin concentration. Pikkujamsa
et al. (11) also demonstrated that HRV in hypertensive
individuals with insulin resistance syndrome is lower than it
is in those without insulin resistance syndrome. Taken
together, our observations suggest that insulin resistance
may serve as the mechanism for the clustering of essential
hypertension and type 2 diabetes.
Echocardiographic findings. In this study, patients with
essential hypertension plus type 2 diabetes had depressed
cardiac diastolic function compared with those without
essential hypertension. These findings are consistent with
the recent studies demonstrating that diastolic dysfunction
is related to depressed BRS (27) and to insulin resistance
(28) in patients with hypertension.
Study limitations. There are several limitations in this
study. First, our study did not include patients with only
essential hypertension or individuals without diabetes and
hypertension. Second, 13 patients in the hypertensive dia-
betic group were treated with calcium channel antagonists
or angiotensin-converting enzyme inhibitors. For ethical
reasons, we did not discontinue the antihypertensive drugs
for an extended period. Antihypertensive therapy has been
reported to improve cardiac autonomic function in hyper-
tensive patients (29,30). However, the discontinued medi-
cation could cause a rebound sympathetic effect, which
could, in turn, mask HRV. Thus, the influences of antihy-
pertensive therapy and its discontinuation should be care-
fully considered. Third, no patients enrolled in this study
underwent coronary angiography. Although ischemic heart
disease could not be completely excluded, severe coronary
artery disease was unlikely to be present in view of normal
treadmill exercise ECG testing and 201thallium cardiac
scintigraphy. Finally, we attributed the depressed cardiac
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autonomic function in hypertensive diabetic patients to the
effects of hypertension. However, the converse interpreta-
tion may also be valid (i.e., cardiac autonomic dysfunction
could contribute to the development of essential hyperten-
sion).
Conclusions. Our findings suggest that essential hyperten-
sion acts synergistically with type 2 diabetes to depress
cardiac reflex vagal and sympathetic function, and they
suggest that insulin resistance may play a pathogenic role in
these processes. Baroreflex sensitivity and 123I-MIBG scin-
tigraphy provide sensitive assessments of cardiac autonomic
control in this population. Future studies are required to
assess the prognostic value of BRS and 123I-MIBG scintig-
raphy in diabetic and hypertensive patients.
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